Sorafenib tosylate for advanced kidney cancer: lucky loser and magic box at the same time
Despite being the very first molecular targeted agents registered for the treatment of advanced kidney cancer (in the post-cytokines setting), Sorafenib seemed to lose its momentum as a credible first-line treatment option, when it proved not to be superior to Interferon within a randomized phase II...
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Formaat: | Boek |
| Gepubliceerd in: |
Frontiers Media S.A.,
2011-09-01T00:00:00Z.
|
| Onderwerpen: | |
| Online toegang: | Connect to this object online. |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|
Internet
Connect to this object online.3rd Floor Main Library
| Plaatsingsnummer: |
A1234.567 |
|---|---|
| Kopie 1 | Beschikbaar |